Gestational diabetes
Drug research and approvals for gestational diabetes: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 120 studies of gestational diabetes are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 120
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Effects Of Core Canister Training in Pregnant Women With History of Gestational Diabetes MellitusNCT07889791 · Not applicable · University of Lahore · starts Jul 20, 2026
- RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes StudyNCT07889388 · Not applicable · Bionime Corporation · starts Jun 9, 2026
- Lumbopelvic Stability in Gestational Diabetes MellitusNCT07851753 · Not reported · Riphah International University · starts May 1, 2026
- Islet Function in Gestational DiabetesNCT07806695 · Phase 1 · Mayo Clinic · starts Sep 1, 2026
- Comparison of Metformin Versus Glyburide for Blood Sugar Control in Women With Gestational DiabetesNCT07802561 · Phase 4 · Nishtar Medical University · starts Apr 18, 2026
- Prenatal Exercise and Glucose RegulationNCT07802262 · Not applicable · University of Central Arkansas · starts Sep 24, 2024
- EARLY Pregnancy GLucose prOfiles in Women With and Without GDM Risk Factors: EARLY-GLOWNCT07783178 · Not reported · DCB Research AG · starts Aug 19, 2026
- Are There Any Clinical Benefits to Screening for Late -Onset Gestational Diabetes Mellitus?"NCT07776314 · Not reported · Izmir Ataturk Training and Research Hospital · starts Mar 13, 2025
- Time-restricted Eating and High-intensity Interval Training After Gestational DiabetesNCT07776886 · Not applicable · Norwegian University of Science and Technology · starts Nov 20, 2026
Phase 3 10
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- Insulin humanInsulin receptor agonist
- Insulin porkInsulin receptor agonist
- CholecalciferolVitamin D receptor agonist
- GlyburideSulfonylurea receptor 1, Kir6.2 blocker
- Insulin susp isophane beefInsulin receptor agonist
- Insulin aspartInsulin receptor agonist
- AcarbosePancreatic alpha-amylase inhibitor
- UrsodiolBile acid receptor FXR agonist
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
Phase 2 1
- VildagliptinDipeptidyl peptidase IV inhibitor
Phase 1 or earlier 2
- ErgocalciferolVitamin D receptor agonist
- Powdered cellulose
How its trials ended
728 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 101 whose ending is known, 33% met their primary endpoint, 21% missed it and 47% stopped early.
- Completed, result not reported28439%
- Ongoing18826%
- Status unknown15521%
- Met its primary endpoint335%
- Stopped: other or unclear284%
- Missed its primary endpoint213%
- Stopped: enrollment or feasibility142%
- Stopped: funding2<1%
- Stopped: lack of efficacy1<1%
- Stopped: safety1<1%
- Stopped: sponsor or business decision1<1%
| Jul 26, 2017 | Expect: a trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of…Insulin degludec/levemir/novorapid | Novo Nordisk | Closed |
| Dec 5, 2016 | Dulaglutide and the preservation of beta-cell function in women with recent gestational diabetes mellitusTrulicity | Mount Sinai Hospital | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA